Compare TG Therapeutics Inc (TGTX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Vanguard Total World Stock Index Fund ETF trades at $160.4. Which is the better fit depends on your goals.
| TGTX | VT | |
|---|---|---|
Market Cap | $8.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $162.39 |
52-Week Low | $26.94 | $134.19 |
Enterprise Value | $8.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
VT trades at $160.92, down 0.5% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The ETF maintains strong global diversification across 10,000+ stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global equity exposure, though near-term volatility may persist due to trade policy uncertainty and midterm election seasonality. Key risks include geopolitical tensions and currency fluctuations affecting international holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
